NovaBridge Biosciences (NBP) Invested Capital (2017 - 2025)

NovaBridge Biosciences (NBP) has 9 years of Invested Capital data on file, last reported at $230.9 million in Q4 2025.

• Invested Capital for Q4 2025 came in at $230.9 million, up 14.8% year-over-year; the trailing twelve-month figure through Dec 2025 was $230.9 million (up 14.8% YoY), and the FY2025 annual result was $230.9 million, up 14.8% from the prior year.
• Invested Capital climbed to $230.9 million in Q4 2025 per NBP's latest filing, from $196.7 million in the prior quarter.
• Over five years, Invested Capital peaked at $845.6 million in Q2 2021 and troughed at $196.7 million in Q2 2025.
• A 5-year average of $371.5 million and a median of $239.7 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital plunged 42.26% in 2022, then grew 14.8% in 2025.
• A 5-year view of Invested Capital shows it stood at $713.2 million in 2021, then sank by 42.26% to $411.8 million in 2022, then sank by 41.04% to $242.8 million in 2023, then declined by 17.15% to $201.2 million in 2024, then advanced by 14.8% to $230.9 million in 2025.
• Business Quant data shows NBP's Invested Capital at $230.9 million in Q4 2025, $196.7 million in Q2 2025, and $198.3 million in Q1 2025.